Tenax Advances Levosimendan Into Phase 2 Trial for PH Caused by Heart Disease
Tenax Therapeutics plans to advance its lead compound, levosimendan, into a Phase 2 clinical trial to treat pulmonary hypertension (PH) associated with heart failure and preserved ejection fraction (PH-HFpEF) — a type of PH related to left heart disease. The company, based in Morrisville, North Carolina, aims to start…